Proactol fat binder clinical data

What is NeOpuntia®?

NeOpuntia® is a 100% natural lipophilic fiber made from dehydrated leaves of cactus Opuntia ficus-indica, and is a result of chemical and solven-free patented process. It is developed and manufactured by BIO SERAE Laboratories SA in France under International Patent Number PCT / FR 02 / 01254.

This active ingredient has been scientifically researched by BIO SERAE since 1996 and suffered numerous clinical studies that showed perfect lipophilic capacity. That means as soon as fats come in contact with NeOpuntia® in the stomach, part of the fat is bound and cannot be absorbed into the small intestine and is eliminated naturally through the gastric system.

Why NeOpuntia® is so effective?

• Numerous scientific researches approved absolute safety and guaranteed lipophilic action by NeOpuntia®.
• This product is certified as GMO-free and allergen-free.
• NeOpuntia® has been approved as Vegetarian (Vegetarian Society (UK), Organic (Ecocert France, 32600) and Kosher.
• NeOpuntia® is main active ingredient in Proactol, that makes it a perfect solution for effective and long term weigh loss.

Clinical Reports

Here we present clinical reports summaries on NeOpuntia® in PDF format (opened with Adobe Acrobat Reader or Foxit Reader):

TNO Report Part-1 2001 – Summary Of Report by the TNO Institute (Netherlands) On Fat
Binding Capacity of a Patented Fibre Complex Of Opuntia Ficus Indica

TNO Report Part-2 2004 – Summary Of Pilot Clinical Study Of a Patented Fibre Complex of Opuntia Ficus Indica On Fat Binding

TNO Report Part-3 2005 – Summary Of TNO Report On Fat Binding Capacity Of a Patented Fibre Complex Of Opuntia Ficus Indica In Presence Of An American Breakfast

Report Part-4 – Effects Of Patented Fibre Complex Of Opuntia Ficus Indica On The Binding Of Non-Specific Fat-Soluble Vitamins, Bile Salts And Acids

Report Part-5 (most recent) – Efficiency of patented fibre complex from Opuntia ficus indica on blood lipids parameters considered as risk factors for Metabolic Syndrome (Syndrome X)

Graphic summary of Proactol efficacy